ZebiAI

ZebiAI Therapeutics is a biotechnology company leveraging machine learning to revolutionize small molecule drug discovery. The company focuses on accelerating target validation and advancing new therapeutics for diseases with significant unmet medical needs. ZebiAI operates in the pharmaceutical and biotechnology markets, primarily serving academic researchers and pharmaceutical companies. Their business model involves combining machine learning algorithms with extensive datasets from small molecule screens to explore vast chemical spaces efficiently. This approach enables the discovery of new drugs in a time and cost-effective manner. ZebiAI generates revenue through partnerships, collaborations, and licensing agreements with pharmaceutical companies and research institutions. The company initially targets oncology, central nervous system (CNS) disorders, and infectious diseases, including coronaviruses. By providing chemical probe molecules through their Chemome initiative, ZebiAI empowers researchers to investigate the functions of understudied proteins, potentially leading to significant scientific breakthroughs.

Keywords: machine learning, drug discovery, target validation, therapeutics, oncology, CNS disorders, infectious diseases, chemical probes, biotechnology, pharmaceutical partnerships.